Skip to main content
Premium Trial:

Request an Annual Quote

Sienna Cancer Diagnostics, Triolab Ink Distribution Deal for Bladder Cancer Test in Sweden

NEW YORK ─  Sienna Cancer Diagnostics said on Tuesday that it has made Triolab the exclusive distributor of its hTERT bladder cancer test in Sweden.

Sienna's in vitro diagnostic test detects the hTERT component of telomerase, a biomarker that aids in the diagnosis of bladder cancer alongside standard urine cytology testing. Under the distribution agreement, Triolab will sell Sienna’s hTERT biomarker test to Swedish pathology laboratories. Melbourne, Australia-based Sienna said that Unilabs, a commercial lab in Sweden, is evaluating the hTERT test for routine use.

Financial and other terms of the agreement were not disclosed.

Mölndal, Sweden-based Triolab is a subsidiary of European life sciences markets distributor AddLife, which has sales in approximately 25 countries, primarily in the Nordic region, Central Europe, and Eastern Europe, Sienna said. Triolab takes over distribution in Sweden from Axlab.

Triolab joins Israel-based Zotal, New Zealand-based Scientle Innovations, and Finland-based Immuno Diagnostics, another AddLife company, as Sienna distributors.